34. Neurofibromatosis Clinical trials / Disease details
Clinical trials : 137 / Drugs : 213 - (DrugBank : 76) / Drug target genes : 87 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02718131 (ClinicalTrials.gov) | March 2016 | 7/3/2016 | A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 (NF1) | A Study of INFUSE Bone Graft (Recombinant Human Bone Morphogenetic Protein-2/Absorbable Collagen Sponge) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis 1 (NF1) | NF1;Congenital Pseudarthrosis of Tibia | Device: INFUSE Bone Graft (BMP-2);Procedure: Control Group | University of Alabama at Birmingham | The Children's Tumor Foundation;Medtronic | Active, not recruiting | 2 Years | 18 Years | All | 54 | N/A | United States;Australia |